Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT02881190
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath